A comparatively lower SORL1 expression level increased metastasis risk and was associated with relatively advanced disease stages, while a higher expression level of SORL1 was associated with a favorable prognosis in BLCA patients. This evidence concerns the gene SORL1 and bladder transitional cell carcinoma.